Akouos, Inc. | MedPath

Mural Oncology's Nemvaleukin Trials Progressing, Data Readouts Anticipated in 2025

6 months ago

• Mural Oncology remains on track with late-stage trials for nemvaleukin alfa, expecting data readouts for platinum-resistant ovarian cancer in late Q1/early Q2 2025. • Top-line results from the ARTISTRY-6 trial cohort 2, focusing on mucosal melanoma, are anticipated in Q2 2025, with a target response rate of 25%. • Candidate nominations for IL-18 and IL-12 programs are expected in Q4 2024, with an IND submission for the IL-18 program planned for Q4 2025. • The company reaffirms its cash runway guidance, projecting sufficient funds to support operations into the fourth quarter of 2025.

Mural Oncology Highlights Nemvaleukin Progress and IL-18 Program at Investor Day

8 months ago

• Mural Oncology's ARTISTRY-7 trial, evaluating nemvaleukin plus pembrolizumab in platinum-resistant ovarian cancer, anticipates interim data in early Q2 2025. • Top-line results from the ARTISTRY-6 trial of nemvaleukin in mucosal melanoma are expected in Q2 2025, potentially supporting a BLA submission. • Mural Oncology plans to submit an Investigational New Drug (IND) application for its IL-18 program to the FDA in Q4 2025.